Emerging roles of epigenetic mechanisms in Parkinson's disease

Functional and Integrative Genomics

Volumn 11, Issue 4, 2011, Pages 523-537

  Habibi, Ehsan ^a   Masoudi Nejad, Ali ^a   Abdolmaleky, Hamid Mostafavi ^b   Haggarty, Stephen J ^c  

^a UNIVERSITY OF TEHRAN   (Iran)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Epigenetics; Neurodegenerative disorders; Neurodevelopmental disorders; Parkinson's disease; Psychiatric disorders; Systems biology

Indexed keywords

ALPHA SYNUCLEIN; AURORA B KINASE; COREPRESSOR PROTEIN; CYCLIN DEPENDENT KINASE 5; HISTONE DEACETYLASE; HISTONE DEACETYLASE 4; HISTONE DEMETHYLASE; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MOTOR; MONOAMINE OXIDASE INHIBITOR; MYOCYTE ENHANCER FACTOR 2; MYOCYTE ENHANCER FACTOR 2D; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEAR RECEPTOR RELATED FACTOR 1; POLYCOMB GROUP PROTEIN; PROTAMINE KINASE; PROTEIN BCL 6; PROTEIN C JUN; PROTEIN COREST; PROTEIN EG5; PROTEIN P53; SELEGILINE; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR PITX3; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; DEACETYLATION; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; EPIGENETICS; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC LINKAGE; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; HUMAN; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; STRUCTURE ANALYSIS; SUMOYLATION; TRANSCRIPTION REGULATION; UBIQUITIN CARBOXYL TERMINAL HYDROLASE ISOZYME L1 GENE; UPREGULATION;

AMINO ACID SEQUENCE; ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HISTONES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; PARKINSON DISEASE; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84855662861     PISSN: 1438793X     EISSN: 14387948     Source Type: Journal    
DOI: 10.1007/s10142-011-0246-z     Document Type: Review

References (158)

1. Abdolmaleky HM, Zhou JR, Thiagalingam S, Smith CL (2008) Epigenetic and pharmacoepigenomic studies of major psychoses and potentials for therapeutics. Pharmacogenomics 9(12):1809-1823. doi:10.2217/14622416.9.12.1809
2. Abel T, Zukin RS (2008) Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol 8(1):57-64. doi:10.1016/j.coph.2007.12.002
3. Adamczyk A, Kazmierczak A (2009) Alpha-synuclein inhibits poly(ADP-ribose) polymerase-1 (PARP-1) activity via NO-dependent pathway. Folia Neuropathol 47(3):247-251
4. Alarcon JM, Malleret G, Touzani K, Vronskaya S, Ishii S, Kandel ER, Barco A (2004) Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: A model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42 (6):947-959. doi:10.1016/j.neuron.2004.05.021 (Pubitemid 38798233)
5. Allis CD, Jenuwein T, Reinberg D (2007) Epigenetics, 1st edn. Cold Spring Harbor Laboratory Press, New York
6. Alvarez-Gonzalez R (2007) Genomic maintenance: The p53 poly(ADP-ribosyl)ation connection. Sci STKE 2007(415):pe68. doi:10.1126/stke. 4152007pe68
7. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23 (2):185-188. doi:10.1038/13810 (Pubitemid 29455390)
8. Arguelles S, Herrera AJ, Carreno-Muller E, de Pablos RM, Villaran RF, Espinosa-Oliva AM, Machado A, Cano J (2010) Degeneration of dopaminergic neurons induced by thrombin injection in the substantia nigra of the rat is enhanced by dexamethasone: Role of monoamine oxidase enzyme. Neurotoxicology 31(1):55-66. doi:10.1016/j.neuro.2009.12.001
9. Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P (2001) The human dopamine transporter gene: Gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol 11(6):449-455 (Pubitemid 33026519)
10. Bannon MJ, Pruetz B, Manning-Bog AB, Whitty CJ, Michelhaugh SK, Sacchetti P, Granneman JG, Mash DC, Schmidt CJ (2002) Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers. Proc Natl Acad Sci USA 99(9):6382-6385. doi:10.1073/pnas.092654299 (Pubitemid 34493320)
11. Barrachina M, Ferrer I (2009) DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol 68(8):880-891. doi:10.1097/NEN.0b013e3181af2e46
12. Bartholdi D, Roelfsema JH, Papadia F, Breuning MH, Niedrist D, Hennekam RC, Schinzel A, Peters DJ (2007) Genetic heterogeneity in Rubinstein-Taybi syndrome: Delineation of the phenotype of the first patients carrying mutations in EP300. J Med Genet 44(5):327-333. doi:10.1136/jmg.2006.046698 (Pubitemid 46732627)
13. Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ (2009) Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: Implications for Alzheimer disease. EMBO Rep 10(1):94-100. doi:10.1038/embor.2008.222
14. Berger SL (2002) Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12(2):142-148 (Pubitemid 34219485)
15. Bird A (2007) Perceptions of epigenetics. Nature 447(7143):396-398. doi:10.1038/nature05913 (Pubitemid 46816744)
16. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular pathways to neurodegeneration. Nat Med 10(Suppl):S2-S9. doi:10.1038/nm1067 (Pubitemid 38901861)
17. Brandabur MM (2007) Recognizing and treating nonmotor aspects of Parkinson's disease. Ann Long Term Care 15(8)
18. Camins A, Verdaguer E, Folch J, Canudas AM, PallasM (2006) The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 19(8):453-460. doi:10.1358/dnp.2006.19.8.1043961 (Pubitemid 46050819)
19. Cao X, Sudhof TC (2001) A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293(5527):115-120. doi:10.1126/science.1058783293/5527/115 (Pubitemid 32625507)
20. Chen RZ, Akbarian S, TudorM, Jaenisch R (2001) Deficiency ofmethyl- CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27(3):327-331. doi:10.1038/85906 (Pubitemid 32201857)
21. Chen Y, Sharma RP, Costa RH, Costa E, Grayson DR (2002) On the epigenetic regulation of the human reelin promoter. Nucleic Acids Res 30(13):2930-2939 (Pubitemid 34778154)
22. Chen KL, Wang SS, Yang YY, Yuan RY, Chen RM, Hu CJ (2009) The epigenetic effects of amyloid-beta(1-40) on global DNA and neprilysin genes in murine cerebral endothelial cells. Biochem Biophys Res Commun 378(1):57-61. doi:10.1016/j. bbrc.2008.10.173
23. Cheung WL, Turner FB, Krishnamoorthy T, Wolner B, Ahn SH, Foley M, Dorsey JA, Peterson CL, Berger SL, Allis CD (2005) Phosphorylation of histone H4 serine 1 during DNA damage requires casein kinase II in S. cerevisiae. Curr Biol 15(7):656-660. doi:10.1016/j.cub.2005.02.049
24. Chia N, Wang L, Lu X, Senut MC, Brenner C, Ruden DM (2011) Hypothesis: Environmental regulation of 5-hydroxymethylcytosine by oxidative stress. Epigenetics 6(7):853-856
25. Chiurazzi P, Pomponi MG, Willemsen R, Oostra BA, Neri G (1998) In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet 7(1):109-113 (Pubitemid 28040744)
26. Chiurazzi P, Pomponi MG, Pietrobono R, Bakker CE, Neri G, Oostra BA (1999) Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet 8(12):2317-2323 (Pubitemid 29525348)
27. Cloos PA, Christensen J, Agger K, Helin K (2008) Erasing the methyl mark: Histone demethylases at the center of cellular differentiation and disease. Genes Dev 22(9):1115-1140. doi:10.1101/gad.1652908 (Pubitemid 351656572)
28. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97(2):571-576 (Pubitemid 30070350)
29. Costa E, Chen Y, Davis J, Dong E, Noh JS, Tremolizzo L, Veldic M, Grayson DR, Guidotti A (2002) REELIN and schizophrenia: A disease at the interface of the genome and the epigenome. Mol Interv 2(1):47-57. doi:10.1124/mi.2.1.47
30. Dai Y, Faller DV (2008) Transcription regulation by class III histone deacetylases (HDACs)-sirtuins. Transl Oncogenomics 3:53-65 (Pubitemid 351586884)
31. Ferrante RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J, Lu P, Smith K, Browne S, BealMF, Kristal BS, Stavrovskaya IG, Hewett S, Rubinsztein DC, Langley B, Ratan RR (2004) Chemotherapy for the brain: The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci 24(46):10335-10342. doi:10.1523/JNEUROSCI.2599-04.2004 (Pubitemid 39552617)
32. Fischer A, Sananbenesi F,Wang X, DobbinM, Tsai LH (2007) Recovery of learning and memory is associated with chromatin remodelling. Nature 447(7141):178-182. doi:10.1038/nature05772 (Pubitemid 46763080)
33. Fishman-Jacob T, Reznichenko L, Youdim MB, Mandel SA (2009) A sporadic Parkinson disease model via silencing of the ubiquitinproteasome/E3 ligase component SKP1A. J Biol Chem 284(47):32835-32845. doi:10.1074/jbc.M109.034223
34. Forneris F, Binda C, Vanoni MA, Battaglioli E, Mattevi A (2005) Human histone demethylase LSD1 reads the histone code. J Biol Chem 280(50):41360-41365. doi:10.1074/jbc.M509549200 (Pubitemid 41832193)
35. Franco R, Li S, Rodriguez-Rocha H, Burns M, Panayiotidis MI (2010) Molecular mechanisms of pesticide-induced neurotoxicity: Relevance to Parkinson's disease. Chem Biol Interact 188(2):289-300. doi:10.1016/j.cbi.2010. 06.003
36. Gao Z, Ye J (2008) Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem Biophys Res Commun 376(4):793-796. doi:10.1016/j.bbrc.2008.09.079
37. Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal MF(2004) Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Med 5(3):235-241. doi:10.1385/NMM:5:3:235 (Pubitemid 40125304)
38. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280(1):556-563. doi:10.1074/jbc.M410210200 (Pubitemid 40165021)
39. Gasser T (2009a) Genomic and proteomic biomarkers for Parkinson disease. Neurology 72(7 Suppl):S27-S31. doi:10.1212/WNL.0b013e318198e054
40. Gasser T (2009b) Molecular pathogenesis of Parkinson disease: Insights from genetic studies. Expert Rev Mol Med 11:e22. doi:10.1017/S1462399409001148
41. Gearhart MD, Corcoran CM, Wamstad JA, Bardwell VJ (2006) Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets. Mol Cell Biol 26(18):6880-6889. doi:10.1128/MCB.00630-06 (Pubitemid 44387637)
42. Geiss-Friedlander R, Melchior F (2007) Concepts in sumoylation: A decade on. Nat Rev Mol Cell Biol 8(12):947-956. doi:10.1038/nrm2293 (Pubitemid 350176509)
43. Gooden DM, Schmidt DM, Pollock JA, Kabadi AM, McCafferty DG(2008) Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B. Bioorg Med Chem Lett 18(10):3047-3051. doi:10.1016/j.bmcl.2008.01.003 (Pubitemid 351680392)
44. Grant PA (2001) A tale of histone modifications. Genome Biol 2(4): REVIEWS0003
45. Gregoire S, Tremblay AM, Xiao L, Yang Q, Ma K, Nie J, Mao Z, Wu Z, Giguere V, Yang XJ (2006) Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation. J Biol Chem 281(7):4423-4433. doi:10.1074/jbc.M509471200 (Pubitemid 43847874)
46. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenisch R, Tsai LH (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459 (7243):55-60. doi:10.1038/nature07925
47. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27(3):322-326. doi:10.1038/85899 (Pubitemid 32201856)
48. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 10(1):32-42. doi:10.1038/nrg2485
49. Hague SM, Klaffke S, BandmannO (2005) Neurodegenerative disorders: Parkinson's disease and Huntington's disease. J Neurol Neurosurg Psychiatry 76(8):1058-1063. doi:10.1136/jnnp.2004.060186 (Pubitemid 41081275)
50. Hakimi MA, Bochar DA, Chenoweth J, Lane WS, Mandel G, Shiekhattar R (2002) A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc Natl Acad Sci USA 99(11):7420-7425. doi:10.1073/pnas.112008599 (Pubitemid 34568706)
51. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP(2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 100(4):2041-2046. doi:10.1073/pnas.0437870100 (Pubitemid 36254570)
52. Huang HS, Akbarian S (2007) GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS One 2(8):e809. doi:10.1371/journal.pone.0000809 (Pubitemid 351419518)
53. Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP, Akbarian S (2007a) Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci 27(42):11254-11262. doi:10.1523/JNEUROSCI.3272-07.2007 (Pubitemid 47621326)
54. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL(2007b) p53 is regulated by the lysine demethylase LSD1. Nature 449(7158):105-108. doi:10.1038/nature06092 (Pubitemid 47373772)
55. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC (1993) Risk factors for Parkinson's disease. Neurology 43(9):1693-1697 (Pubitemid 23307937)
56. Inzelberg R, Jankovic J (2007) Are Parkinson disease patients protected from some but not all cancers? Neurology 69 (15):1542-1550. doi:10.1212/01.wnl. 0000277638.63767.b8 (Pubitemid 47537862)
57. Ishii A, Nonaka T, Taniguchi S, Saito T, Araic T, Mann D, Iwatsubo T, Hisanaga S, Goedert M, Hasegawa M (2007) Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies. FEBS Lett 581(24):4711-4717 (Pubitemid 47418797)
58. Iwata A, Miura S, Kanazawa I, Sawada M, Nukina N (2001) Alphasynuclein forms a complex with transcription factor Elk-1. J Neurochem 77(1):239-252 (Pubitemid 32245098)
59. Jacobs FM, van Erp S, van der Linden AJ, von Oerthel L, Burbach JP, Smidt MP (2009) Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression. Development 136(4):531-540. doi:10.1242/dev.029769
60. Jankovic J (2008) Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368-376. doi:10.1136/jnnp.2007.131045 (Pubitemid 351441488)
61. Jankovic J, Chen S, LeWD (2005) The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol 77(1-2):128-138. doi:10.1016/j.pneurobio.2005.09.001 (Pubitemid 41654775)
62. Jellinger KA (2000) Cell death mechanisms in Parkinson's disease. J Neural Transm 107(1):1-29 (Pubitemid 30077039)
63. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53(Suppl 3):S26-S36. doi:10.1002/ana.10483 (Pubitemid 36368560)
64. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293(5532):1074-1080 (Pubitemid 32758077)
65. Jie Z, Li T, Jia-Yun H, Qiu J, Ping-Yao Z, Houyan S (2009) Trans-2- phenylcyclopropylamine induces nerve cells apoptosis in zebrafish mediated by depression of LSD1 activity. Brain Res Bull 80 (1-2):79-84. doi:10.1016/j. brainresbull.2009.04.013
66. Jiricny J,MenigattiM(2008) DNA cytosine demethylation: Are we getting close? Cell 135(7):1167-1169. doi:10.1016/j.cell.2008.12.008
67. Johnson KA, Conn PJ, Niswender CM (2009) Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets 8(6):475-491
68. Joo HY, Zhai L, Yang C, Nie S, Erdjument-Bromage H, Tempst P, Chang C, Wang H (2007) Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature 449 (7165):1068-1072. doi:10.1038/nature06256 (Pubitemid 350014605)
69. Joseph B, Wallen-Mackenzie A, Benoit G, Murata T, Joodmardi E, Okret S, Perlmann T (2003) p57(Kip2) cooperates with Nurr1 in developing dopamine cells. Proc Natl Acad Sci USA 100 (26):15619-15624. doi:10.1073/pnas.2635658100 (Pubitemid 38021039)
70. Jowaed A, Schmitt I, Kaut O, Wullner U (2010) Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 30(18):6355-6359. doi:10.1523/JNEUROSCI.6119-09.2010
71. Khochbin S, Kao HY (2001) Histone deacetylase complexes: Functional entities or molecular reservoirs. FEBS Lett 494(3):141-144 (Pubitemid 32322671)
72. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26(13):3169-3179. doi:10.1038/sj.emboj.7601758 (Pubitemid 47057498)
73. Klose RJ, Zhang Y (2007) Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 8 (4):307-318. doi:10.1038/nrm2143 (Pubitemid 46474659)
74. Kohno R, Sawada H, Kawamoto Y, Uemura K, Shibasaki H, Shimohama S (2004) BDNF is induced by wild-type alphasynuclein but not by the two mutants, A30P or A53T, in glioma cell line. Biochem Biophys Res Commun 318(1):113-118. doi:10.1016/j.bbrc.2004.04.012 (Pubitemid 38526252)
75. Konradi C, Westin JE, Carta M, Eaton ME, Kuter K, Dekundy A, Lundblad M, Cenci MA (2004) Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis 17(2):219-236. doi:10.1016/j.nbd.2004.07.005 (Pubitemid 39345778)
76. Kontopoulos E, Parvin JD, FeanyMB (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15(20):3012-3023. doi:10.1093/hmg/ddl243 (Pubitemid 44530705)
77. Korzus E, Rosenfeld MG, Mayford M (2004) CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42(6):961-972. doi:10.1016/j.neuron.2004.06.002 (Pubitemid 38798234)
78. Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4):693-705. doi:10.1016/j.cell.2007.02.005 (Pubitemid 46273577)
79. Koyama-Nasu R, David G, Tanese N (2007) The F-box protein Fbl10 is a novel transcriptional repressor of c-Jun. Nat Cell Biol 9 (9):1074-1080. doi:10.1038/ncb1628 (Pubitemid 47342313)
80. Kriaucionis S, Heintz N (2009) The nuclear DNA base 5- hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324(5929):929-930. doi:10.1126/science.1169786
81. Latham JA, Dent SY (2007) Cross-regulation of histone modifications. Nat Struct Mol Biol 14(11):1017-1024. doi:10.1038/nsmb1307 (Pubitemid 350060331)
82. Le W, Pan T, Huang M, Xu P, Xie W, Zhu W, Zhang X, Deng H, Jankovic J (2008) Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci 273(1-2):29-33. doi:10.1016/j.jns.2008.06.007
83. Leng Y, Chuang DM (2006) Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 26(28):7502-7512. doi:10.1523/JNEUROSCI.0096-06.2006 (Pubitemid 44315219)
84. Lesage S, Brice A (2009) Parkinson's disease: From monogenic forms to genetic susceptibility factors. Hum Mol Genet 18(R1):R48-R59. doi:10.1093/hmg/ddp012
85. Levy OA, Malagelada C, Greene LA (2009) Cell death pathways in Parkinson's disease: Proximal triggers, distal effectors, and final steps. Apoptosis 14(4):478-500. doi:10.1007/s10495-008-0309-3
86. Li W, Liu M (2011) Distribution of 5-hydroxymethylcytosine in different human tissues. J Nucleic Acids 2011:870726. doi:10.4061/2011/870726
87. Li YJ, Fu XH, Liu DP, Liang CC (2004) Opening the chromatin for transcription. Int J Biochem Cell Biol 36(8):1411-1423. doi:10.1016/j.biocel. 2003.11.003 (Pubitemid 38625822)
88. Li J, Dani JA, Le W (2009) The role of transcription factor Pitx3 in dopamine neuron development and Parkinson's disease. Curr Top Med Chem 9(10):855-859
89. Lim ACB, Hou ZB, Goh CP, Qi RZ (2004) Protein kinase CK2 is an inhibitor of the neuronal Cdk5 kinase. J Biol Chem 279 (45):46668-46673 (Pubitemid 39518313)
90. LiuM, Aneja R, Sun X, Xie S,Wang H,Wu X, Dong JT, LiM, Joshi HC, Zhou J (2008) Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase. J Biol Chem 283(51):35783-35788. doi:10.1074/jbc.M806860200
91. Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H, Gokce O, Kuhn A, Xiang Z, Maxwell MM, Reeves SA, Bates GP, Neri C, Thompson LM,Marsh JL, Kazantsev AG (2010) SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA 107 (17):7927-7932. doi:10.1073/pnas.1002924107
92. MacDonald JL, Roskams AJ (2008) Histone deacetylases 1 and 2 are expressed at distinct stages of neuro-glial development. Dev Dyn 237(8):2256-2267. doi:10.1002/dvdy.21626
93. Mandel SA, Fishman T, Youdim MB (2007) Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD. Parkinsonism Relat Disord 13(Suppl 3):S242-S247. doi:10.1016/S1353-8020(08)70009-9 (Pubitemid 351215248)
94. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis NK (2003) A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 114(5):635-645 (Pubitemid 37159259)
95. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, Fan G, Sun YE (2003) DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302 (5646):890-893. doi:10.1126/science.1090842 (Pubitemid 37339633)
96. Matsumoto L, Takuma H, Tamaoka A, Kurisaki H, Date H, Tsuji S, Iwata A (2010) CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One 5(11):e15522. doi:10.1371/journal. pone.0015522
97. Maze I, Covington HE 3rd, Dietz DM, LaPlant Q, Renthal W, Russo SJ, Mechanic M, Mouzon E, Neve RL, Haggarty SJ, Ren Y, Sampath SC, Hurd YL, Greengard P, Tarakhovsky A, Schaefer A, Nestler EJ (2010) Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science 327(5962):213-216. doi:10.1126/science.1179438
98. Mena MA, Rodriguez-Navarro JA, Ros R, de Yebenes JG (2008) On the pathogenesis and neuroprotective treatment of Parkinson disease: What have we learned from the genetic forms of this disease? Curr Med Chem 15(23):2305-2320
99. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16 (10):4623-4635 (Pubitemid 41416446)
100. Migliore L, Coppede F (2009) Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res 667(1-2):82-97. doi:10.1016/j.mrfmmm.2008.10.011
101. Mimasu S, Sengoku T, Fukuzawa S, Umehara T, Yokoyama S (2008) Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A. Biochem Biophys Res Commun 366(1):15-22. doi:10.1016/j.bbrc.2007.11.066 (Pubitemid 50007727)
102. Miranda TB, Jones PA (2007) DNA methylation: The nuts and bolts of repression. J Cell Physiol 213(2):384-390. doi:10.1002/jcp.21224 (Pubitemid 47509717)
103. Mogi M, Kondo T, Mizuno Y, Nagatsu T (2007) p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett 414(1):94-97. doi:10.1016/j. neulet.2006.12.003 (Pubitemid 46241643)
104. Monaco L, Kolthur-Seetharam U, Loury R, Murcia JM, de Murcia G, Sassone-Corsi P (2005) Inhibition of Aurora-B kinase activity by poly(ADP-ribosyl)ation in response toDNAdamage. Proc NatlAcad Sci USA 102(40):14244-14248. doi:10.1073/pnas.0506252102 (Pubitemid 41429683)
105. Monier K, Mouradian S, Sullivan KF (2007) DNA methylation promotes Aurora-B-driven phosphorylation of histone H3 in chromosomal subdomains. J Cell Sci 120(Pt 1):101-114. doi:10.1242/jcs.03326 (Pubitemid 46206653)
106. Nair VD, McNaught KS, Gonzalez-Maeso J, Sealfon SC, Olanow CW(2006) p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem 281 (51):39550-39560. doi:10.1074/jbc. M603950200 (Pubitemid 46041915)
107. Narlikar GJ, Fan HY, Kingston RE (2002) Cooperation between complexes that regulate chromatin structure and transcription. Cell 108(4):475-487 (Pubitemid 34260873)
108. Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG (2008) Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem 106(1):486-494. doi:10.1111/j.1471- 4159.2008.05417.x (Pubitemid 351840228)
109. Nicholson TB, Chen T (2009) LSD1 demethylates histone and nonhistone proteins. Epigenetics 4(3):129-132
110. Oei SL, Griesenbeck J, Schweiger M, Ziegler M (1998) Regulation of RNA polymerase II-dependent transcription by poly(ADP-ribosyl) ation of transcription factors. J Biol Chem 273(48):31644-31647 (Pubitemid 29177091)
111. Outeiro TF, Grammatopoulos TN, Altmann S, Amore A, Standaert DG, Hyman BT, Kazantsev AG (2007a) Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models. Biochem Biophys Res Commun 357(3):596-602. doi:10.1016/j.bbrc.2007.03. 163 (Pubitemid 46661843)
112. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG(2007b) Sirtuin 2 inhibitors rescue alpha-synuclein- mediated toxicity in models of Parkinson's disease. Science 317 (5837):516-519. doi:10.1126/science.1143780 (Pubitemid 47196116)
113. Pieper HC, Evert BO, Kaut O, Riederer PF, Waha A, Wullner U (2008) Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability. Neurobiol Dis 32(3):521-527. doi:10.1016/j.nbd.2008.09.010
114. Renthal W, Nestler EJ (2008) Epigenetic mechanisms in drug addiction. Trends Mol Med 14(8):341-350. doi:10.1016/j. molmed.2008.06.004
115. Roelfsema JH, White SJ, Ariyurek Y, Bartholdi D, Niedrist D, Papadia F, Bacino CA, den Dunnen JT, van Ommen GJ, Breuning MH, Hennekam RC, Peters DJ (2005) Genetic heterogeneity in Rubinstein- Taybi syndrome: Mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet 76(4):572-580. doi:10.1086/429130 (Pubitemid 40432165)
116. Roth SY, Denu JM, Allis CD (2001) Histone acetyltransferases. Annu Rev Biochem 70:81-120. doi:10.1146/annurev.biochem.70.1.81 (Pubitemid 32662206)
117. Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler JP, Boutillier AL(2003) Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 22(24):6537-6549. doi:10.1093/emboj/cdg615 (Pubitemid 38009601)
118. SaijoK,Winner B, CarsonCT, Collier JG, Boyer L, RosenfeldMG,Gage FH, Glass CK (2009) A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammationinduced death. Cell 137(1):47-59. doi:10.1016/j.cell.2009.01.038
119. Santpere G, Nieto M, Puig B, Ferrer I (2006) Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies. Neurosci Lett 397(1-2):30-34. doi:10.1016/j.neulet.2005.11.062 (Pubitemid 43340453)
120. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ 3rd, Kandel ER, Duff K, Kirkwood A, Shen J (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by agedependent neurodegeneration. Neuron 42(1):23-36 (Pubitemid 38456965)
121. Scarpa S, Fuso A, D'Anselmi F, Cavallaro RA (2003) Presenilin 1 gene silencing by S-adenosylmethionine: A treatment for Alzheimer disease? FEBS Lett 541(1-3):145-148 (Pubitemid 36428933)
122. Scoumanne A, Chen X (2007) The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J Biol Chem 282(21):15471-15475. doi:10.1074/jbc. M701023200 (Pubitemid 47093261)
123. Scoumanne A, Chen X (2008) Protein methylation: A new mechanism of p53 tumor suppressor regulation. Histol Histopathol 23(9):1143-1149
124. Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, Noebels J, Armstrong D, Paylor R, Zoghbi H (2002) Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35(2):243-254 (Pubitemid 34876728)
125. Shi Y, Whetstine JR (2007) Dynamic regulation of histone lysine methylation by demethylases. Mol Cell 25(1):1-14. doi:10.1016/j.molcel.2006.12. 010 (Pubitemid 46049067)
126. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7):941-953. doi:10.1016/j. cell.2004.12.012 (Pubitemid 40037608)
127. Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y (2005) Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell 19(6):857-864. doi:10.1016/j.molcel.2005.08.027 (Pubitemid 41316679)
128. Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ, Biniszkiewicz D, Jaenisch R, Laird PW, Akbarian S (2007) DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One 2(9):e895. doi:10.1371/journal.pone.0000895 (Pubitemid 351425881)
129. Smith PD, Mount MP, Shree R, Callaghan S, Slack RS, Anisman H, Vincent I, Wang X, Mao Z, Park DS (2006) Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 26(2):440-447. doi:10.1523/JNEUROSCI.2875- 05.2006 (Pubitemid 43237108)
130. Spencer VA, Davie JR (1999) Role of covalent modifications of histones in regulating gene expression. Gene 240(1):1-12 (Pubitemid 29516431)
131. Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, Matson S, Goodrich S, Markey AL, Cormier K, Hagerty SW, Smith K, Ryu H, Ferrante RJ (2007) Modulation of nucleosome dynamics in Huntington's disease. Hum Mol Genet 16(10):1164-1175. doi:10.1093/hmg/ddm064 (Pubitemid 47062713)
132. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413(6857):739-743. doi:10.1038/35099568 (Pubitemid 33009952)
133. Sterner DE, Berger SL (2000) Acetylation of histones and transcriptionrelated factors. Microbiol Mol Biol Rev 64(2):435-459
134. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403(6765):41-45 (Pubitemid 30038513)
135. Sugars KL, Brown R, Cook LJ, Swartz J, Rubinsztein DC (2004) Decreased cAMP response element-mediated transcription: An early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J Biol Chem 279(6):4988-4999. doi:10.1074/jbc. M310226200 (Pubitemid 38199095)
136. Szargel R, Rott R, Engelender S (2008) Synphilin-1 isoforms in Parkinson's disease: Regulation by phosphorylation and ubiquitylation. Cell Mol Life Sci 65(1):80-88. doi:10.1007/s00018-007-7343-0
137. Tabolacci E, Pietrobono R, Moscato U, Oostra BA, Chiurazzi P, Neri G(2005) Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet 13(5):641-648. doi:10.1038/sj.ejhg.5201393 (Pubitemid 40691406)
138. Tabolacci E, Moscato U, Zalfa F, Bagni C, Chiurazzi P, Neri G (2008) Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations. Eur J Hum Genet 16 (12):1487-1498. doi:10.1038/ejhg.2008.130
139. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324 (5929):930-935. doi:10.1126/science.1170116
140. Takai D, Jones PA (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 99 (6):3740-3745. doi:10.1073/pnas.052410099 (Pubitemid 34252176)
141. Tang BL, Chua CE (2008) SIRT1 and neuronal diseases. Mol Aspects Med 29(3):187-200. doi:10.1016/j.mam.2007.02.001 (Pubitemid 351615154)
142. Tang X,Wang X, Gong X, TongM, Park D, Xia Z,Mao Z (2005) Cyclindependent kinase 5 mediates neurotoxin-induced degradation of the transcription factor myocyte enhancer factor 2. J Neurosci 25 (19):4823-4834. doi:10.1523/JNEUROSCI. 1331-05.2005 (Pubitemid 40664130)
143. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW (1999) Parkinson disease in twins: An etiologic study. JAMA 281(4):341-346 (Pubitemid 29061038)
144. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ (2007) How chromatin-binding modules interpret histone modifications: Lessons from professional pocket pickers. Nat Struct Mol Biol 14 (11):1025-1040 (Pubitemid 350060344)
145. Thalhammer A, Hansen AS, El-Sagheer AH, Brown T, Schofield CJ(2011) Hydroxylation of methylated CpG dinucleotides reverses stabilisation of DNA duplexes by cytosine 5-methylation. Chem Commun (Camb) 47(18):5325-5327. doi:10.1039/c0cc05671e
146. Topark-Ngarm A, Golonzhka O, Peterson VJ, Barrett B Jr, Martinez B, Crofoot K, Filtz TM, Leid M (2006) CTIP2 associates with the NuRD complex on the promoter of p57KIP2, a newly identified CTIP2 target gene. J Biol Chem 281(43):32272-32283. doi:10.1074/jbc.M602776200 (Pubitemid 46036781)
147. Tsai WW, Nguyen TT, Shi Y, Barton MC (2008) p53-targeted LSD1 functions in repression of chromatin structure and transcription in vivo. Mol Cell Biol 28(17):5139-5146. doi:10.1128/MCB.00287-08
148. Turner BM (2002) Cellular memory and the histone code. Cell 111 (3):285-291 (Pubitemid 35341385)
149. Verdin E, Dequiedt F, Kasler HG (2003) Class II histone deacetylases: Versatile regulators. Trends Genet 19(5):286-293 (Pubitemid 36507011)
150. Wang SC, Oelze B, Schumacher A (2008) Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One 3(7):e2698. doi:10.1371/journal.pone. 0002698
151. Wang Y, Zhang H, Chen Y, Sun Y, Yang F, YuW, Liang J, Sun L, Yang X, Shi L, Li R, Li Y, Zhang Y, Li Q, Yi X, Shang Y (2009) LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138(4):660-672. doi:10.1016/j. cell.2009.05.050
152. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, Harry J, Rice DC, Maloney B, Chen D, Lahiri DK, Zawia NH(2008) Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): Evidence for a developmental origin and environmental link for AD. J Neurosci 28(1):3-9. doi:10.1523/JNEUROSCI.4405-07.2008
153. Yang JO, Kim WY, Jeong SY, Oh JH, Jho S, Bhak J, Kim NS (2009a) PDbase: A database of Parkinson's disease-related genes and genetic variation using substantia nigra ESTs. BMC Genomics 10 (Suppl 3):S32. doi:10.1186/1471-2164-10- S3-S32
154. Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, Mao Z(2009b) Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 323(5910):124-127. doi:10.1126/science.1166088
155. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23 (12):2369-2380. doi:10.1038/sj.emboj.7600244 (Pubitemid 38954844)
156. Zhao X, Sternsdorf T, Bolger TA, Evans RM, Yao TP (2005) Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. Mol Cell Biol 25 (19):8456-8464. doi:10.1128/MCB.25.19.8456-8464. 2005 (Pubitemid 41369167)
157. Zhou W, Wang X, Rosenfeld MG (2009) Histone H2A ubiquitination in transcriptional regulation and DNA damage repair. Int J Biochem Cell Biol 41(1):12-15. doi:10.1016/j.biocel.2008.09.016
158. Zuccato C, Cattaneo E (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5(6):311-322. doi:10.1038/nrneurol. 2009.54